| Literature DB >> 32351012 |
Yukimura Higashiura1, Marenao Tanaka1,2, Masato Furuhashi1,3, Masayuki Koyama1,4, Hirofumi Ohnishi1,4, Keita Numata5, Takashi Hisasue5, Nagisa Hanawa5, Norihito Moniwa1, Tetsuji Miura1.
Abstract
AIMS/Entities:
Keywords: Bicarbonate ions; Nonvolatile acid; Urine pH
Mesh:
Substances:
Year: 2020 PMID: 32351012 PMCID: PMC7610131 DOI: 10.1111/jdi.13284
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Figure 1Flow chart of the selected study participants. Among 28,990 participants enrolled in 2006, a total of 12,476 participants (men/women: 8,027/4,449) were finally recruited for analyses in the present study.
Characteristics of the recruited participants
| Total | Men | Women |
| |
|---|---|---|---|---|
|
|
|
| ||
| Age (years) | 47 ± 9 | 48 ± 9 | 47 ± 9 | <0.001 |
| Body mass index | 23.1 ± 3.3 | 23.9 ± 3.0 | 21.6 ± 3.2 | <0.001 |
| Obesity | 3,780 (30.3) | 3,055 (38.1) | 725 (16.3) | <0.001 |
| Systolic blood pressure (mmHg) | 116 ± 16 | 119 ± 15 | 110 ± 16 | <0.001 |
| Diastolic blood pressure (mmHg) | 74 ± 11 | 77 ± 10 | 69 ± 10 | <0.001 |
| Smoking habit | 4,362 (35.8) | 3,532 (45.1) | 830 (19.1) | <0.001 |
| Alcohol drinking habit | 3,274 (26.2) | 2,742 (34.2) | 532 (12.0) | <0.001 |
| Family history of DM | 2,174 (17.4) | 1,270 (15.8) | 904 (20.3) | <0.001 |
| Medications | ||||
| Antihypertensive drugs | 714 (9.9) | 809 (10.1) | 299 (6.7) | <0.001 |
| Antidyslipidemic drugs | 1,108 (8.9) | 315 (3.9) | 171 (3.8) | 0.836 |
| Biochemical data | ||||
| Albumin (g/dL) | 4.3 ± 0.2 | 4.4 ± 0.2 | 4.3 ± 0.2 | <0.001 |
| eGFR (mL/min/1.73m2) | 85 ± 13 | 84 ± 12 | 87 ± 14 | <0.001 |
| Uric acid (mg/dL) | 5.4 ± 1.4 | 6.0 ± 1.2 | 4.3 ± 0.9 | <0.001 |
| Fasting glucose (mg/dL) | 89 ± 9 | 91 ± 9 | 86 ± 8 | <0.001 |
| HbA1c (%) | 5.2 ± 0.3 | 5.2 ± 0.3 | 5.1 ± 0.3 | <0.001 |
| AST (U/L) | 21 (18–26) | 22 (19–28) | 19 (16–22) | <0.001 |
| ALT (U/L) | 20 (15–30) | 25 (18–36) | 15 (12–20) | <0.001 |
| γGTP (U/L) | 30 (19–55) | 62 (27–72) | 18 (14–26) | <0.001 |
| Total cholesterol (mg/dL) | 204 ± 33 | 205 ± 33 | 203 ± 33 | 0.052 |
| LDL cholesterol (mg/dL) | 121 ± 30 | 123 ± 30 | 118 ± 30 | <0.001 |
| HDL cholesterol (mg/dL) | 61 ± 15 | 56 ± 14 | 69 ± 15 | <0.001 |
| Triglycerides (mg/dL) | 91 (63–135) | 109 (77–157) | 67 (50–93) | <0.001 |
| Urine pH | 5.9 ± 0.7 | 5.9 ± 0.7 | 6.0 ± 0.8 | <0.001 |
Variables are expressed as number (%), mean ± standard deviation or median (interquartile ranges).
Obesity was defined as body mass index ≥25. γGTP, gamma glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.
Characteristics of the participants divided by urine pH at baseline
| U‐pH ≤5.0 | U‐pH = 5.5 | U‐pH = 6.0 | U‐pH ≥6.5 |
| |
|---|---|---|---|---|---|
|
| |||||
| Men | 1,610 | 2,442 | 1,675 | 2,300 | – |
| Women | 987 | 1,171 | 814 | 1,477 | – |
| Age (years) | |||||
| Men | 50 ± 8 | 47 ± 9 | 47 ± 9 | 48 ± 10 | <0.001 |
| Women | 48 ± 9 | 46 ± 9 | 47 ± 10 | 48 ± 9 | <0.001 |
| Body mass index | |||||
| Men | 24.2 ± 3.1 | 23.8 ± 3.1 | 23.8 ± 3.0 | 23.6 ± 2.9 | <0.001 |
| Women | 21.5 ± 3.2 | 21.6 ± 3.3 | 21.6 ± 3.4 | 21.7 ± 3.1 | 0.568 |
| Obesity | |||||
| Men | 713 (44.3) | 916 (37.5) | 630 (37.6) | 796 (34.6) | <0.001 |
| Women | 155 (15.7) | 203 (17.3) | 134 (16.5) | 233 (15.8) | 0.684 |
| Fasting glucose (mg/dL) | |||||
| Men | 92 ± 10 | 91 ± 9 | 91 ± 8 | 90 ± 8 | <0.001 |
| Women | 86 ± 8 | 86 ± 8 | 86 ± 8 | 85 ± 8 | 0.510 |
| HbA1c (%) | |||||
| Men | 5.3 ± 0.4 | 5.2 ± 0.3 | 5.2 ± 0.3 | 5.2 ± 0.3 | <0.001 |
| Women | 5.2 ± 0.3 | 5.1 ± 0.3 | 5.1 ± 0.3 | 5.2 ± 0.3 | 0.002 |
Variables are expressed as number (%) or mean ± standard deviation.
Obesity was defined as body mass index ≥25. HbA1c, hemoglobin A1c; U‐pH, urine pH.
Figure 2Cumulative incidence of diabetes mellitus in four groups of urine pH at baseline. (a) Kaplan–Meier survival curve analyses for cumulative incidence of diabetes mellitus in men (n = 8,027) with baseline urine pH (U‐pH) ≤5.0 (n = 1,610), 5.5 (n = 2,442), 6.0 (n = 1,675) and ≥6.5 (n = 2,300). (b) Kaplan–Meier survival curve analyses for cumulative incidence of diabetes mellitus in women (n = 4,449) with baseline urine pH (U‐pH) ≤5.0 (n = 987), 5.5 (n = 1,171), 6.0 (n = 814) and ≥6.5 (n = 1,477). *P < 0.001.
Cox proportional hazard analyses for new onset of diabetes mellitus in men
| Unadjusted | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| |
| U‐pH ≤5.0 | 1.93 (1.54–2.52) | <0.001 | 1.52 (1.18–1.95) | <0.001 | 1.39 (1.07–1.79) | 0.001 |
| U‐pH 5.5 | 1.46 (1.15–1.85) | 0.001 | 1.33 (1.04–1.69) | 0.002 | 1.17 (0.91–1.50) | 0.197 |
| U‐pH 6.0 | 1.18 (0.89–1.55) | 0.231 | 1.09 (0.83–1.44) | 0.504 | 1.05 (0.79–1.39) | 0.711 |
| U‐pH ≥6.5 | Reference | – | Reference | – | Reference | – |
| Age (per 10 years) | – | – | 1.17 (1.06–1.30) | <0.001 | 1.18 (1.06–1.32) | <0.001 |
| Obesity | – | – | 1.91 (1.60–2.29) | <0.001 | 1.76 (1.46–2.12) | <0.001 |
| Fasting glucose (≥100 mg/dL) | – | – | 9.7 (8.0–11.7) | <0.001 | 9.7 (8.0–11.8) | <0.001 |
| Smoking habit | – | – | – | – | 1.76 (1.46–2.11) | <0.001 |
| Alcohol drinking habit | – | – | – | – | 0.83 (0.68–1.05) | 0.140 |
| Family history of DM | – | – | – | – | 1.41 (1.15–1.73) | <0.001 |
| Antihypertensive drugs | – | – | – | – | 1.20 (0.93–1.54) | 0.145 |
| Antidyslipidemic drugs | – | – | – | – | 1.63 (1.18–2.25) | <0.001 |
| (AIC 8,960) | (AIC 8,195) | (AIC 7,788) | ||||
n = 8,027. †Obesity was defined as body mass index ≥25. AIC, Akaike's information criterion; CI, confidence interval; DM, diabetes mellitus; HR, hazard ratio; U‐pH, urine pH.
Cox proportional hazards analyses for new onset of diabetes mellitus in women
| Unadjusted | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| |
| U‐pH ≤5.0 | 1.18 (0.73–1.90) | 0.481 | 1.03 (0.64–1.66) | 0.888 | 1.02 (0.62–1.67) | 0.930 |
| U‐pH 5.5 | 1.25 (0.80–1.95) | 0.322 | 1.11 (0.70–1.75) | 0.635 | 1.17 (0.74–1.86) | 0.494 |
| U‐pH 6.0 | 1.08 (0.64–1.81) | 0.762 | 0.99 (0.59–1.67) | 0.987 | 1.01 (0.60–1.72) | 0.952 |
| U‐pH ≥6.5 | Reference | – | Reference | – | Reference | – |
| Age (per 10 years) | – | – | 1.31 (1.08–1.58) | 0.004 | 1.35 (1.10–1.66) | 0.004 |
| Obesity | – | – | 2.61 (1.82–3.73) | <0.001 | 2.61 (1.80–3.77) | <0.001 |
| Fasting glucose (≥100 mg/dL) | – | – | 13.3 (9.2–19.0) | <0.001 | 12.4 (8.5–17.9) | <0.001 |
| Smoking habit | – | – | – | – | 1.38 (0.89–2.15) | 0.142 |
| Alcohol drinking habit | – | – | – | – | 0.93 (0.54–1.60) | 0.797 |
| Family history of DM | – | – | – | – | 1.73 (1.18–2.54) | 0.004 |
| Antihypertensive drugs | – | – | – | – | 1.20 (0.72–2.00) | 0.464 |
| Antidyslipidemic drugs | – | – | – | – | 1.65 (0.92–9.75) | 0.091 |
| (AIC 2,104) | (AIC 1,871) | (AIC 1,802) | ||||
n = 4,449. †Obesity was defined as body mass index ≥25. AIC, Akaike's information criterion; CI, confidence interval; DM, diabetes mellitus; HR, hazard ratio; U‐pH, urine pH.